ArticleInternational ophthalmology2026
Faricimab for treatment-naïve nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate 1- and 2-year real-world outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration (nAMD) and to explore factors associated with visual acuity change, including polarization-sensitive OCT (PS-OCT)-derived polarimetric entropy (PE).
methodsThis retrospective single-center study included 27 treatment-naïve nAMD eyes initiating faricimab; all eyes were evaluable at 1 year (n = 27) and 18 at 2 years (n = 18). BCVA (logMAR), central retinal thickness (CRT), PE, and entropy-defined HRF-like foci (HEF)-related metrics were assessed. Associations with ΔlogMAR (post-pre) were examined using multivariable linear regression. Prespecified baseline-BCVA-adjusted and EZ-adjusted sensitivity models were additionally performed. EZ integrity was graded at the fovea and included in sensitivity analyses.
resultsBCVA improved from 0.40 ± 0.28 to 0.20 ± 0.23 at 1 year (P < 0.0001). In the 2-year cohort, BCVA improved from 0.35 ± 0.28 to 0.15 ± 0.20 at 1 year (P = 0.0003) and 0.12 ± 0.17 at 2 years (P = 0.0004). CRT decreased from 337.5 ± 159.8 to 186.7 ± 47.3 µm at 1 year (P < 0.0001) and from 337.3 ± 185.9 to 185.1 ± 46.4 µm at 1 year (P = 0.0019) and 181.2 ± 60.9 µm at 2 years (P < 0.0001). Mean PE increased at 1 year (0.44 ± 0.06 to 0.46 ± 0.05; P < 0.0001) but not from baseline to 2 years (P = 0.81). In multivariable analyses, ΔPE was associated with 1-year ΔlogMAR (β; - 2.7 to - 2.8; P ≤ 0.01) together with MNV subtype, whereas at 2 years the incremental association of ΔPE was attenuated in baseline-adjusted and EZ-adjusted sensitivity analyses in the 2-year completer cohort.
conclusionsFaricimab treatment was associated with sustained functional and anatomical improvement in treatment-naïve nAMD. PE change may serve as a complementary imaging marker associated with visual improvement, particularly at 1 year, while longer-term associations warrant confirmation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.